Protagonist Ther Stock Price, News & Analysis

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced that its CEO, Dinesh V. Patel, Ph.D., will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference from November 30 to December 3, 2020. Registered attendees can view the presentation on the conference site until December 3, and it will also be accessible via the company's Investors section starting November 30. Protagonist focuses on developing peptide-based therapeutics for unmet medical needs, with three clinical-stage assets targeting blood disorders and inflammatory bowel disease.

Protagonist Therapeutics (NASDAQ:PTGX) announced that its President and CEO, Dinesh V. Patel, will join a fireside chat at the Jefferies Virtual 2020 London Healthcare Conference. The event is scheduled for November 17, 2020, at 5:35 p.m. GMT (12:35 p.m. EST). A live and archived webcast will be accessible via the company's website and the provided links.

Protagonist is a clinical-stage biopharmaceutical company focusing on developing peptide-based therapeutics for significant medical needs, currently advancing three clinical-stage assets.

Protagonist Therapeutics (PTGX) reported its third-quarter 2020 financial results, highlighting ongoing Phase 2 clinical studies for its assets PTG-300, PN-943, and PTG-200.

Notably, PTG-300 received orphan designation from the EMA, with full enrollment expected by mid-2021 and a pivotal study slated for the second half of 2021.

In Q3 2020, Protagonist raised $25.3 million through its ATM program and reported revenue of $13.1 million, up from $4.1 million in Q3 2019. Despite a net loss of $7.8 million, losses narrowed from $16.4 million in the same period last year.

Protagonist Therapeutics (NASDAQ: PTGX) announced acceptance of one oral and four poster presentations at the American Society for Hematology (ASH) annual meeting, scheduled for December 5-8, 2020. The data includes results from the ongoing Phase 2 study of PTG-300 for polycythemia vera as of August 2020. The conference will provide a platform to share findings and analysis of patient data, emphasizing the potential of PTG-300, a hepcidin mimetic. CEO Dinesh V. Patel highlighted PTG-300's transformative potential for patients and stressed the goal of achieving regulatory approval efficiently.

Protagonist Therapeutics (Nasdaq:PTGX) announced on October 31, 2020 that it granted an inducement award to Nora Boyer, its newly appointed Vice President of Medical Affairs. The award includes an option to purchase 40,000 shares at an exercise price of $18.95, the closing price on October 30, 2020. Shares will vest over a four-year period, with 25% vesting after one year. This grant complies with NASDAQ Marketplace Rule 5635(c)(4>. Protagonist develops peptide-based therapeutics for unmet medical needs, with three clinical-stage assets including PTG-300 and PTG-200.

Protagonist Therapeutics (NASDAQ: PTGX) announced the progression of two new oral peptide IL-23 receptor antagonists, PN-235 and PN-232, into clinical development as part of its collaboration with Janssen Biotech. These additions complement PTG-200, which is in a Phase 2 study for Crohn's disease. The company aims to leverage these candidates for multiple indications, anticipating the initiation of a Phase 1 study for PN-235 by 2020's fourth quarter. The partnership allows Protagonist to receive milestone payments while Janssen oversees further development.

Protagonist Therapeutics (NASDAQ:PTGX) announced that the European Medicines Agency granted orphan drug designation for PTG-300, aimed at treating polycythemia vera. This synthetic peptide mimetic of hepcidin also received similar designation from the FDA. The company is moving forward with a Phase 2 clinical trial and anticipates launching a pivotal study in mid-2021. Polycythemia vera affects about 100,000 patients in the U.S. and EU, underscoring the need for effective treatments. Orphan drug designation provides advantages for clinical development.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit on September 23, 2020, at 8 a.m. EDT. Dinesh V. Patel, Ph.D., the company's President and CEO, will engage in a fireside chat during the event. A live and archived webcast will be available via this link and on the Protagonist website. Protagonist focuses on novel peptide-based therapeutics for unmet medical needs, with three clinical-stage assets including PTG-300 and PTG-200.

Protagonist Therapeutics (Nasdaq:PTGX) announced on September 15, 2020, the issuance of an inducement award to Matthew Gosling, the newly appointed Executive Vice President and General Counsel. This award includes an option to purchase 100,000 shares of common stock at an exercise price of $21.66, matching the stock's closing price on the grant date. The shares will vest over four years, with the first 25% vesting after one year. The award is part of Mr. Gosling's employment terms approved by the company's compensation committee.